Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Braeburn Gets CRL For CAM2038 In Opioid Use Disorder, Yields Ground To Indivior

Executive Summary

Braeburn was in a position to launch its buprenorphine injection CAM2038 within a month and a half of its Jan. 19 PDUFA date, putting the opioid addiction therapy on the market around the same time as Indivior's Sublocade, but now there may be several months between the products' launches.

Advertisement

Related Content

2018 Complete Response Letters: Efficacy Issues Drove Most Product Rejections
While You Were Out: News In Brief
Keeping Track: US FDA Approvals For Tibsovo, Kisqali And Second Neupogen Biosimilar
Indivior Withdraws 2018 Guidance Due To Competitive Pressures On Suboxone, Sublocade
Indivior Withdraws 2018 Guidance Due To Competitive Pressures On Suboxone, Sublocade
Keeping Track: Shutdown Edition
Sublocade Approval Grows Indivior's Opioid Addiction Franchise In Competitive Market
Braeburn's Buprenorphine Clears Advisory Committee, But US FDA Likely To Limit Dosage

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100249

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel